{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:56:26Z","timestamp":1793073386431,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Botulinum neurotoxin type A (BoNT-A) is an effective pharmacological treatment for the management of cervical dystonia (CD) that requires repeated administration at variable intervals. We explored patient perceptions of the impact of CD and the waning of BoNT-A therapeutic effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An internet-based survey was conducted through Carenity, a global online patient community, from May to September 2019. Eligible respondents were adults with CD who had\u2009\u2265\u20092 previous BoNT-A injections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>209 respondents (81% females; mean age of 49.7\u00a0years) met the screening criteria. The mean BoNT-A injection frequency was 3.9 injections\/year. The mean reported onset of BoNT-A therapeutic effect was 11.7\u00a0days and the time to peak effect was 4.5\u00a0weeks. Symptom re-emergence between injections was common (88%); the time from injection to symptom re-emergence was 73.6\u00a0days (~\u200910.5\u00a0weeks). Treatment was not reported to completely abolish symptoms, even at peak effect. However, symptom severity was rated (0\u2009=\u2009no symptoms; 10\u2009=\u2009very strong symptoms) as lowest at the peak of treatment effects (mean scores\u2009~\u20093\/10), increasing as the effects of treatment start waning (~\u20095.5\/10) and was strongest one day before the next session (~\u20097\u20138\/10). The impact of CD on quality of life followed the same \u2018rollercoaster\u2019 pattern.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This survey highlights the burden of CD symptoms, even in patients undergoing regular treatment. Symptom re-emergence is common and has significant impact on daily activities and quality of life. Greater awareness of the therapeutic profile of BoNT-A treatment should lead to better informed therapeutic discussions and planning.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-020-10217-7","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T19:31:02Z","timestamp":1600284662000},"page":"903-912","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia"],"prefix":"10.1007","volume":"268","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7100-4701","authenticated-orcid":false,"given":"Cynthia","family":"Comella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Pain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Azoulai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savary","family":"Om","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"issue":"2","key":"10217_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/mds.870060206","volume":"6","author":"J Chan","year":"1991","unstructured":"Chan J, Brin MF, Fahn S (1991) Idiopathic cervical dystonia: clinical characteristics. Mov Disord 6(2):119\u2013126. https:\/\/doi.org\/10.1002\/mds.870060206","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"10217_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/s0733-8619(08)80003-5","volume":"26","author":"M Stacy","year":"2008","unstructured":"Stacy M (2008) Epidemiology, clinical presentation, and diagnosis of cervical dystonia. Neurol Clin 26(Suppl 1):23\u201342. https:\/\/doi.org\/10.1016\/s0733-8619(08)80003-5","journal-title":"Neurol Clin"},{"issue":"12","key":"10217_CR3","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1002\/mds.20670","volume":"20","author":"IM Skogseid","year":"2005","unstructured":"Skogseid IM, Roislien J, Claussen B, Kerty E (2005) Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia. Mov Disord 20(12):1604\u20131609. https:\/\/doi.org\/10.1002\/mds.20670","journal-title":"Mov Disord"},{"issue":"5","key":"10217_CR4","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1136\/jnnp.72.5.608","volume":"72","author":"Y Ben-Shlomo","year":"2002","unstructured":"Ben-Shlomo Y, Camfield L, Warner T (2002) What are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry 72(5):608\u2013614","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10217_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.clineuro.2008.09.023","volume":"111","author":"T Pekmezovic","year":"2009","unstructured":"Pekmezovic T, Svetel M, Ivanovic N, Dragasevic N, Petrovic I, Tepavcevic DK, Kostic VS (2009) Quality of life in patients with focal dystonia. Clin Neurol Neurosurg 111(2):161\u2013164. https:\/\/doi.org\/10.1016\/j.clineuro.2008.09.023","journal-title":"Clin Neurol Neurosurg"},{"issue":"7","key":"10217_CR6","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s00415-002-0733-1","volume":"249","author":"J Muller","year":"2002","unstructured":"Muller J, Kemmler G, Wissel J, Schneider A, Voller B, Grossmann J, Diez J, Homann N, Wenning GK, Schnider P, Poewe W, Austrian Botulinum T, Dystonia Study G (2002) The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol 249(7):842\u2013846. https:\/\/doi.org\/10.1007\/s00415-002-0733-1","journal-title":"J Neurol"},{"issue":"1","key":"10217_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1468-1331.2010.03042.x","volume":"18","author":"A Albanese","year":"2011","unstructured":"Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G, Gasser T, Krauss JK, Nardocci N, Newton A, Valls-Sole J (2011) EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 18(1):5\u201318. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03042.x","journal-title":"Eur J Neurol"},{"key":"10217_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.0000000000002560","volume":"86","author":"DM Simpson","year":"2016","unstructured":"Simpson DM, Hallett M, Ashman EJ (2016) Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Neurology 86:1\u20139","journal-title":"Neurology"},{"issue":"6","key":"10217_CR9","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.parkreldis.2006.06.002","volume":"12","author":"DD Truong","year":"2006","unstructured":"Truong DD, Jost WH (2006) Botulinum toxin: clinical use. Parkinsonism Relat Disord 12(6):331\u2013355. https:\/\/doi.org\/10.1016\/j.parkreldis.2006.06.002","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"10217_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/jnnp.64.1.13","volume":"64","author":"W Poewe","year":"1998","unstructured":"Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, Kessler KR, Ceballos-Baumann AO, Ohly A, Oertel W, Kunig G (1998) What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 64(1):13\u201317","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10217_CR11","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/mds.26760","volume":"31","author":"W Poewe","year":"2016","unstructured":"Poewe W, Burbaud P, Castelnovo G, Jost WH, Ceballos-Baumann AO, Banach M, Potulska-Chromik A, Ferreira JJ, Bihari K, Ehler E, Bares M, Dzyak LA, Belova AN, Pham E, Liu WJ, Picaut P (2016) Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: a randomized-controlled trial. Mov Disord 31(11):1649\u20131657. https:\/\/doi.org\/10.1002\/mds.26760","journal-title":"Mov Disord"},{"issue":"8","key":"10217_CR12","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1212\/wnl.40.8.1213","volume":"40","author":"P Greene","year":"1990","unstructured":"Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E (1990) Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 40(8):1213\u20131218. https:\/\/doi.org\/10.1212\/wnl.40.8.1213","journal-title":"Neurology"},{"key":"10217_CR13","unstructured":"Dysport (abobotulinumtoxinA). Full US prescribing information. https:\/\/dysport.com. Accessed August 2020."},{"key":"10217_CR14","unstructured":"Botox (onabotulinumtoxinA). Full US prescribing information. https:\/\/botoxmedical.com. Accessed August 2020."},{"issue":"12","key":"10217_CR15","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1007\/s00415-019-09527-2","volume":"266","author":"C Colosimo","year":"2019","unstructured":"Colosimo C, Charles D, Misra VP, Maisonobe P, Om S (2019) How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study. J Neurol 266(12):3038\u20133046. https:\/\/doi.org\/10.1007\/s00415-019-09527-2","journal-title":"J Neurol"},{"issue":"3","key":"10217_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3111\/13696998.2011.653726","volume":"15","author":"KD Sethi","year":"2012","unstructured":"Sethi KD, Rodriguez R, Olayinka B (2012) Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ 15(3):419\u2013423. https:\/\/doi.org\/10.3111\/13696998.2011.653726","journal-title":"J Med Econ"},{"issue":"11","key":"10217_CR17","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","volume":"64","author":"R Benecke","year":"2005","unstructured":"Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64(11):1949\u20131951","journal-title":"Neurology"},{"key":"10217_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858","author":"M Castel\u00e3o","year":"2017","unstructured":"Castel\u00e3o M, Marques RE, Duarte GS, Rodrigues FB, Ferreira J, Sampaio C, Moore A, Costa J (2017) Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858","journal-title":"Cochrane Database Syst Rev"},{"key":"10217_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.576117","author":"A Esquenazi","year":"2020","unstructured":"Esquenazi A, Delgado MR, Hauser RA, Picaut P, Foster K, Lysandropoulos A, Gracies J-M (2020) Duration of symptom relief between injections for AbobotulinumtoxinA (Dysport\u00ae) in spastic paresis and cervical dystonia: comparison of evidence from clinical studies. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2020.576117","journal-title":"Front Neurol"},{"key":"10217_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7586-2","author":"C Comella","year":"2015","unstructured":"Comella C, Bhatia K (2015) An international survey of patients with cervical dystonia. J Neurol. https:\/\/doi.org\/10.1007\/s00415-014-7586-2","journal-title":"J Neurol"},{"issue":"6","key":"10217_CR21","first-page":"12","volume":"14","author":"RA Saha","year":"2015","unstructured":"Saha RA, Worth PF, Stamford J (2015) Assessing quality of life in Parkinson\u2019s in routine clinical settings. ACNR 14(6):12\u201314","journal-title":"ACNR"},{"issue":"7","key":"10217_CR22","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00702-010-0424-5","volume":"117","author":"M Stacy","year":"2010","unstructured":"Stacy M (2010) The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson\u2019s disease. J Neural Transm 117(7):837\u2013846. https:\/\/doi.org\/10.1007\/s00702-010-0424-5","journal-title":"J Neural Transm"},{"key":"10217_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/mdc3.12574","volume":"5","author":"CN Prudente","year":"2018","unstructured":"Prudente CN, Zetterberg L, Bring A, Bradnam L, Kimberley TJ (2018) Systematic review of rehabilitation in focal dystonias: classification and recommendations. Mov Disord Clin Pract 5:237\u2013245. https:\/\/doi.org\/10.1002\/mdc3.12574","journal-title":"Mov Disord Clin Pract"},{"issue":"12","key":"10217_CR24","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1002\/mds.21145","volume":"21","author":"C Tassorelli","year":"2006","unstructured":"Tassorelli C, Mancini F, Balloni L, Pacchetti C, Sandrini G, Nappi G, Martignoni E (2006) Botulinum toxin and neuromotor rehabilitation: an integrated approach to idiopathic cervical dystonia. Mov Disord 21(12):2240\u20132243. https:\/\/doi.org\/10.1002\/mds.21145","journal-title":"Mov Disord"},{"key":"10217_CR25","first-page":"187","volume":"27","author":"MA Queiroz","year":"2012","unstructured":"Queiroz MA, Chien HF, Sekeff-Sallem FA, Barbosa ER (2012) Physical therapy program for cervical dystonia: a study of 20 cases. Funct Neurol 27:187\u2013192","journal-title":"Funct Neurol"},{"key":"10217_CR26","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1002\/acn3.50900","volume":"6","author":"L Klingelhoefer","year":"2019","unstructured":"Klingelhoefer L, Chaudhuri KR, Kamm C, Martinez-Martin P, Bhatia K, Sauerbier A, Kaiser M, Rodriguez-Blazquez C, Balint B, Untucht R, Hall LJ, Mildenstein L, Wienecke M, Martino D, Gregor O, Storch A, Reichmann H (2019) Validation of a self-completed Dystonia Non-Motor Symptoms Questionnaire. Ann Clin Transl Neurol 6:2054\u20132065. https:\/\/doi.org\/10.1002\/acn3.50900","journal-title":"Ann Clin Transl Neurol"}],"updated-by":[{"DOI":"10.1007\/s00415-020-10255-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:00:00Z","timestamp":1603670400000}}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10217-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-020-10217-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10217-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T19:50:56Z","timestamp":1631735456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-020-10217-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10217"],"URL":"https:\/\/doi.org\/10.1007\/s00415-020-10217-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,16]]},"assertion":[{"value":"15 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00415-020-10255-1","URL":"https:\/\/doi.org\/10.1007\/s00415-020-10255-1","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Comella serves on the editorial board of Clinical Neuropharmacology and Sleep Medicine. She receives compensation\/honoraria for services as a consultant or an advisory committee member: Acorda Therapeutics, Allergan, Inc; Lundbeck Ltd.; Merz Pharmaceuticals; Acadia Pharmaceuticals; Ipsen Pharmaceuticals, Jazz. Pharmaceuticals, Neurocrine Biosciences Inc., Revance Therapeutic, Sunovion., AEON Biopharma. She receives royalties from Cambridge University Press and Wolters Kluwer. She receives research support from the Parkinson\u2019s Disease Foundation. Joaquim J. Ferreira has held consultancy functions with GlaxoSmithKline, Novartis, TEVA, Lundbeck, Solvay, Abbott, Abbvie, BIAL, Merck-Serono, Merz, Ipsen, Biogen, NeuroDerm, Zambon, Sunovion, Affiris, ONO; has received lecture fees from Biogen and BIAL, Sunovion, ONO, Zambon, Abbvie; has received grants from GlaxoSmithKline, Grunenthal, MSD, Allergan, Novartis, Funda\u00e7\u00e3o MSD (Portugal), Medtronic and Teva; has been employed by Faculdade de Medicina de Lisboa and CNS\u2014Campus Neurol\u00f3gico S\u00e9nior. Marion Azoulai and Emilie Pain are employed by Carenity who received funding from Ipsen for conducting this survey. Savary Om was an Ipsen employee at the time of study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests"}},{"value":"Clinical Research Ethics Committee or Independent Review Board approval was not required for this exploratory patient satisfaction survey.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All respondents provided informed consent to participate.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}